Boron containing small molecules as antiprotozoal agents
This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
1. A compound having a structure according to the following formulae:
wherein
R a is substituted or unsubstituted heteroaryl or substituted or unsubstituted heterocycloalkyl;
R b is halogen or substituted or unsubstituted alkyl;
R 3a is H or unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 alkyl; R 3b is H or unsubstituted C 1 or C 2 or C 3 or C 4 or C 5 or C 6 alkyl; with the proviso that R 3a and R 3b cannot both be H;
or a salt thereof.
2. The compound of claim 1 , or a salt thereof, wherein R a is substituted or unsubstituted morpholinyl or substituted or unsubstituted pyrazolyl or substituted or unsubstituted pyrrolopyridinyl or substituted or unsubstituted pyrrolidinyl or substituted or unsubstituted piperizinyl or substituted or unsubstituted pyridazinyl or substituted or unsubstituted piperidinyl or substituted or unsubstituted imidazolyl or substituted or unsubstituted azetidinyl or substituted or unsubstituted triazolyl.
3. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
4. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
5. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
6. The compound of claim 1 , or a salt thereof, which is:
7. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
8. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
9. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
10. The compound of claim 1 , or a salt thereof, which is:
11. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
12. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
13. The compound of claim 1 , or a salt thereof, having a structure according to the following formula:
14. The compound of claim 1 , or a salt thereof which is
15. A combination comprising the compound of claim 1 , together with at least one other therapeutically active agent.
16. A pharmaceutical formulation comprising:
a) the compound of claim 1 , or a salt thereof; and
b) a pharmaceutically acceptable excipient.
17. The pharmaceutical formulation of claim 16 , wherein the pharmaceutical formulation is a unit dosage form.
18. The pharmaceutical formulation of claim 16 , wherein the salt of said compound of a preceding claim is a pharmaceutically acceptable salt.
19. A method of killing and/or inhibiting the growth of a protozoa, comprising: contacting the protozoa with an effective amount of the compound of claim 1 , thereby killing and/or inhibiting the growth of the protozoa.
20. The method of claim 19 , wherein the protozoa is a trypanosomatid.
21. The method of claim 19 , wherein the protozoa is Trypanosoma congolense.
22. A method of treating a protozoa-associated disease in an animal, comprising: administering to the animal a therapeutically effective amount of the compound of claim 1 , thereby treating the protozoa-associated disease.
23. The method of claim 22 , wherein the disease is African animal trypanosomiasis.
24. The method of claim 22 , wherein the animal is a cow or a bull.
25. The compound of claim 1 , or a salt thereof, which is:
26. The method of claim 22 , wherein the disease is associated with a Trypanosoma.